Back to Oncology
Oncologyv2021Evidence-Based

Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus

Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy and provides management recommendations

Clinical Input Parameters

mg/dL
Range: 70 — 1000 mg/dL
Clinical Assessment
Awaiting Parameters
irae grade
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Grading based on fasting glucose levels (mg/dL), presence of ketosis/T1DM evidence, and symptom severity: Grade 1 (>160 mg/dL, no ketosis, mild symptoms), Grade 2 (160-250 mg/dL OR ketosis at any level, moderate symptoms), Grade 3 (250-500 mg/dL, severe symptoms), Grade 4 (>500 mg/dL, life-threatening symptoms)

Clinical Pearls & Practice Notes

  • Based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
  • Immune checkpoint inhibitor-induced diabetes mellitus often presents as fulminant Type 1 diabetes
  • 67.4% of cases present with diabetic ketoacidosis (DKA)
  • Low C-peptide levels detected in 91.8% of cases indicating acute onset
  • Ketosis or T1DM evidence at any glucose level warrants at least Grade 2 classification
  • Grade 2+ requires urgent endocrine consultation
  • ICPi therapy can often be resumed after glucose control is achieved for Grade 1-2
  • Grade 3-4 typically requires permanent ICPi discontinuation
  • Monitor for HbA1c, fasting C-peptide, and GADA autoantibodies
  • Distinguish from pre-existing diabetes or steroid-induced hyperglycemia
  • Consider continuous glucose monitoring for severe cases
  • Multidisciplinary team approach recommended (oncology, endocrinology, pharmacy)

Evidence & Literature Citations

  1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.
  2. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.
  3. Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral Damage: Insulin-Dependent Diabetes Induced by Immune Checkpoint Inhibitors. Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002.
  4. Akturk HK, Alkanani A, Karanchi H, Nair V, Michels AW, Ostrom QT, et al. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019 Sep;36(9):1075-1081. doi: 10.1111/dme.14050.

Score Interpretation Ranges

Tier 11 – 1 pts

Mild - Asymptomatic or mild symptoms

Tier 22 – 2 pts

Moderate - Moderate symptoms, able to perform ADLs

Tier 33 – 3 pts

Severe - Severe symptoms, unable to perform ADLs

Tier 44 – 4 pts

Life-threatening - Severe symptoms, life-threatening consequences

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.